Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Interest & Investment Income (2021 - 2025)

Krystal Biotech's Interest & Investment Income history spans 5 years, with the latest figure at $6.7 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 7.46% year-over-year to $6.7 million; the TTM value through Dec 2025 reached $28.2 million, down 4.84%, while the annual FY2025 figure was $28.2 million, 4.84% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $6.7 million at Krystal Biotech, up from $6.6 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $7.6 million in Q1 2024 and bottomed at $30000.0 in Q2 2021.
  • The 5-year median for Interest & Investment Income is $5.7 million (2023), against an average of $4.3 million.
  • The largest annual shift saw Interest & Investment Income skyrocketed 3784.29% in 2022 before it fell 9.41% in 2025.
  • A 5-year view of Interest & Investment Income shows it stood at $70000.0 in 2021, then surged by 3784.29% to $2.7 million in 2022, then soared by 172.53% to $7.4 million in 2023, then decreased by 2.36% to $7.2 million in 2024, then fell by 7.46% to $6.7 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Interest & Investment Income are $6.7 million (Q4 2025), $6.6 million (Q3 2025), and $7.5 million (Q2 2025).